AtmosR
Pioneering treatments to restore autonomous breathing and safety for those with rare central nervous system disorders.
Pioneering treatments to restore autonomous breathing and safety for those with rare central nervous system disorders.
AtmosR is a biotech startup that focuses on developing pioneering treatments for rare and severe disorders of the central nervous system. Their flagship drug, ATS-003, aims to restore autonomous breathing in CCHS patients, thus eliminating a critical risk and enabling greater independence. Founded in 2019, the company is based in Aix en Provence and Paris. The most recent investment, a non-equity assistance investment, was received on 03 January 2022 from Incubateur Impulse.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Non Equity Assistance | Unknown | 1 |
|
03 Jan 2022 |
No recent news or press coverage available for AtmosR.
We care about your data, and we'd love to use cookies make your experience better.